FDG-Pet Scan: A New Paradigm for Follicular Lymphoma Management.

Abstract

In the present review, the reader will be led to the most relevant observations that prompted oncologists and haematologist to consider FDG-PET/CT as a new paradigm for FL management in clinical practice. The role of functional imaging in lymphoma staging, restaging, prognostication, and metabolic tumour volume computing will be reviewed in detail. Moreover, a special focus will be addressed to technical and practical aspects of PET scan reporting, which have been set during the last decade to ensure the reproducibility of the therapeutic results. Finally, the predictive role of PET/CT on long-term treatment outcome will be compared with another well-known prognosticator as minimal residual disease (MRD) detection by Immunoglobulin gene rearrangement assessment.

High-grade B-cell Lymphoma with MYC and BCL2 Rearrangement Arising from Follicular Lymphoma: Presentation as a Large Peripancreatic Mass

“…It is hypothesized that, initially, follicular lymphoma is comprised of multiple clones that have an indolent behavior. Transformation occurs through the clonal evolution where the most aggressive clone undergoes expansion [5,16]. Most commonly, follicular lymphoma transforms into a DLBCL [17].…”

“…Radiographically, CT and MRI are useful tools in assessing the extent of the disease. FDG-PET studies are instrumental in identifying patients with high risk of transformation [5].…”

Diagnosis and Treatment of Synchronous Lymphoma and Digestive System Carcinoma: Report of Four Cases and Literature Review

“…A PET-CT scan was recommended recently for initial staging, identifying extranodal lesion and response assessment in both FL and DLBCL, which is more accurate and sensitive than contrast-enhanced CT scanning (12)(13)(14)(15). However, false-positive results with a PET-CT in FL have been described and occurred with inflammatory, normal physiologic processes, additional malignancy, and benign lesions.…”

Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation

“…Positron emission tomography (PET) is recognised as a standard post-treatment evaluation tool in FL, due to its ability to distinguish between viable residual tumour and necrosis or fibrosis in residual mass(es) often present after treatment, thereby allowing more precise response evaluation than CT [52]. Several studies have reported significantly longer PFS in patients with negative PET status at end of treatment compared with those with positive PET status [53][54][55].…”